These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. Carrier M, Ménasché P, Levy JH, Newman MF, Taylor KM, Haverich A, Chen JC, Shernan SK, Van de Werf F, van der Laan M, Todaro TG, Adams PX, Verrier ED. J Thorac Cardiovasc Surg; 2006 Feb; 131(2):352-6. PubMed ID: 16434264 [Abstract] [Full Text] [Related]
4. Is the aortic valve pathology type different for early and late mortality in concomitant aortic valve replacement and coronary artery bypass surgery? Gunay R, Sensoz Y, Kayacioglu I, Tuygun AK, Balci AY, Kisa U, Demirtas MM, Yekeler I. Interact Cardiovasc Thorac Surg; 2009 Oct; 9(4):630-4. PubMed ID: 19625469 [Abstract] [Full Text] [Related]